Samantha Hitchcock | Authors


Mutational Testing an Important Factor in AML Treatment Paradigm, Smith Explains

March 27, 2019

During a Targeted Oncology live case-based peer perspectives program, B. Douglas Smith, MD, discussed his clinical consideration for the management of acute myeloid leukemia. Smith explained his treatment decisions during the dinner event in 2 case scenarios of patients with AML.

Jabbour Reviews TKI Options in Case Study of Chronic Phase CML

March 21, 2019

During a Targeted Oncology case-based peer perspectives program, Elias Jabbour, MD, discussed his clinical considerations for the management of chronic myeloid leukemia in chronic phase. Jabbour explained his treatment decisions during the live event based on a case scenario of a patient with CML-CP.

CMS Mulls Opposition to Downsizing Part D Protected Drug Classes

March 15, 2019

The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.

Greater Communication and Care Coordination Needed to Stimulate Growth of Immunotherapy, Says ACCC

March 14, 2019

Less than 20% of healthcare providers feel very comfortable administering and prescribing appropriate and timely treatment to manage adverse events associated with immuno-oncology therapy, according to an independent needs assessment conducted by the ACCC IO Institute.